Not surprising. It’s a lot easier to draw a nega
Post# of 148190
Certainly bad trial results in one possibility, but only one. I wouldn’t be a bit surprised if we’ve been shoved to the back burner by the FDA. They seem to be in a panic over mutations getting past BP’s beloved vaccines.
Of course the shorts love this delay, and it’s making them $$. Hopefully we will see something positive before the SP drops below the $4 up listing threshold.